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Abstract
Introduction—The Alzheimer’s Disease Research Summits of 2012 and 2015 incorporated 
experts from academia, industry, and nonprofit organizations to develop new research directions to 
transform our understanding of Alzheimer’s disease (AD) and propel the development of critically 
needed therapies. In response to their recommendations, big data at multiple levels are being 
generated and integrated to study network failures in disease. We used metabolomics as a global 
biochemical approach to identify peripheral metabolic changes in AD patients and correlate them 
to cerebrospinal fluid pathology markers, imaging features, and cognitive performance.
Methods—Fasting serum samples from the Alzheimer’s Disease Neuroimaging Initiative (199 
control, 356 mild cognitive impairment, and 175 AD participants) were analyzed using the 
AbsoluteIDQ-p180 kit. Performance was validated in blinded replicates, and values were 
medication adjusted.
Results—Multivariable-adjusted analyses showed that sphingomyelins and ether-containing 
phosphatidylcholines were altered in preclinical biomarker-defined AD stages, whereas 
acylcarnitines and several amines, including the branched-chain amino acid valine and α-
aminoadipic acid, changed in symptomatic stages. Several of the analytes showed consistent 
associations in the Rotterdam, Erasmus Rucphen Family, and Indiana Memory and Aging Studies. 
Partial correlation networks constructed for Aβ1–42, tau, imaging, and cognitive changes provided 
initial biochemical insights for disease-related processes. Coexpression networks interconnected 
key metabolic effectors of disease.
Discussion—Metabolomics identified key disease-related metabolic changes and disease-
progression-related changes. Defining metabolic changes during AD disease trajectory and its 
relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.
Keywords
Metabolomics; Metabonomics; Pharmacometabolomics; Pharmacometabonomics; Biomarkers; 
Serum; Metabolism; Systems biology; Biochemical networks; Precision medicine; Alzheimer’s 
disease; Dementia; Branched-chain amino acids; Sphingomyelins; Phospholipids; Acylcarnitines
1. Introduction
Alzheimer’s disease (AD) is the most common cause of dementia. An anticipated 136 
million people will be affected by dementia by 2050, presenting major global health and 
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economic challenges. There are currently no treatments that modify AD; hence, AD remains 
the largest unmet medical need within neurological disorders [1,2].
Many biochemical processes are affected in AD, including amyloid precursor protein 
metabolism, phosphorylation of tau protein, oxidative stress, impaired energetics, 
mitochondrial dysfunction, inflammation, membrane lipid dysregulation, and 
neurotransmitter pathway disruption [3,4]. Impaired cerebral glucose uptake occurs decades 
before the onset of cognitive dysfunction in AD [5], and neurotoxicity associated with Aβ is 
thought to participate in impaired neuronal energetics including mitochondrial dysfunction 
and release of reactive oxygen species. Growing evidence supports the concept that insulin 
resistance can contribute to AD pathogenesis, and therefore, AD could be regarded as a 
metabolic disease mediated in part by brain insulin and insulin-like growth factor resistance 
[3]. Mapping the trajectory of biochemical changes in AD is therefore becoming a priority 
as filling knowledge gaps about disease mechanisms and their link to metabolic processes 
can lead to developing much-needed biomarkers and therapies [3]. How does peripheral 
metabolism, diet, gut microbiome, and exposome impact the metabolic heath of the brain, 
and thus cognitive function? Which pathways are affected by genes that have been 
implicated in AD, such as presenilin 1 (PSEN1) and PS2 or apolipoprotein E (APOE) 
genes? Biochemical information elucidating these questions is critical for developing drugs 
that target enzymes and transporters which regulate metabolism.
Metabolomics provides powerful tools for mapping global biochemical changes in disease 
and treatment [6–10]. In contrast to classical biochemical approaches that focus on single 
metabolites or reactions, metabolomics and lipidomics approaches simultaneously identify 
and quantify hundreds to thousands of metabolites [11–19]. Measurement of large numbers 
of metabolites enables network analysis approaches and provides means to identify critical 
metabolic drivers in disease pathophysiology [20]. Initial small-scale metabolomics studies 
in AD have highlighted metabolic alterations including ceramide–sphingomyelin pathways 
[10], glycero-phosphatidylcholines (aa = diacyl, ae = acyl–alkyl) [PC] [15,21], PE 
plasmalogens [22,23], amines [24], and mitochondrial defects [25] among others [13,14]. 
Metabolic networks have linked central perturbations in norepinephrine and purines with 
elevated cerebrospinal fluid (CSF) tau, and changes in tryptophan and methionine to 
decreased Aβ levels [18]. More recently, the ARIC Neurocognitive Study identified PC aa 
C36:1 as being linked to lower risk of dementia; however, no metabolite from the panel 
measured added significantly to prediction of dementia beyond routine clinical variables 
[26]. A recent plasma–pathology correlative study found that plasma ceramides C16:0, 
C18:1, C20:0, and C24:1 and monohexosylceramides C18:1 and C24:1 were elevated in 
those with autopsy-confirmed AD pathology [27], but these metabolites did not differentiate 
AD from dementia with Lewy bodies. An autopsy study of frontal cortex metabolites from 
AD patients versus controls showed six central metabolic pathways were altered along with 
glycerophospholipid metabolism and aspartate metabolism. A metabolomics study in an AD 
mouse model (APPswe/PS1deltaE9 double transgenic) found abnormalities in polyamine 
metabolism, essential amino acids, branched-chain amino acids (BCAAs), and serotonin, as 
well as phospholipid and acylcarnitine homeostasis with brain changes preceding those in 
the blood [28]. Although these studies highlight specific metabolic underpinnings of AD, not 
all metabolomics findings have been replicated. For example, a metabolomics study of two 
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separate cohorts—the Baltimore Longitudinal Study of Aging, and the Age, Gene/
Environment Susceptibility-Reykjavik Study—did not replicate an earlier finding 
[11,12,15].
Earlier metabolomics studies had major limitations, including not accounting for important 
confounds such as impact of medications use; small studies that lacked evaluation across 
data sets; limited ability to connect peripheral metabolic changes with central changes to 
define what might be related, and lack of attempts to connect metabolic changes within a 
pathway and network context. Network biology and “network medicine” approaches have 
become important tools to dissect molecular mechanisms triggering neurodegeneration [29]. 
This approach accounts for the fact that complex diseases arise from alterations in multiple 
genes, proteins, and metabolites, and a network may be described as an interaction map 
among the wide range of biological entities which contribute to disease. As many of the 
metabolites that are associated with AD are interconnected through metabolic pathways, 
cofactors, and common intermediates, changes to one metabolite can entail several others, as 
well as have downstream effects on other coregulated pathways. A systems biology 
approach integrating metabolites and their interrelations (for instance quantified by partial 
correlations) in metabolic networks can provide important mechanistic insights about how 
biochemical reactions are dysregulated during different stages of disease. In contrast to 
looking at single dysregulated metabolite at a time, the visualization of changes in the 
metabolic network captures the totality of influences on interconnected biochemical 
reactions in far more informative ways and allows one to follow these changes over disease 
stages.
In this large study, we profiled baseline serum samples from the Alzheimer’s Disease 
Neuroimaging Initiative–1 (ADNI-1) cohort where vast data exist on each patient including 
cognitive decline and imaging changes over many years, information on CSF markers, 
genetics, and other omics data. We used CSF biomarkers to define early metabolic changes 
in cognitively normal participants who have CSF pathology and to evaluate metabolic 
signatures that might be related to Aβ1–42 and tau pathology. Using partial correlation 
networks, we defined progressive metabolic changes that accompany changes in CSF 
Aβ1–42, CSF tau, brain structure, and cognition [30], whereas coexpression networks were 
used to connect key metabolic changes implicated in disease. The relationship of metabolites 
with longitudinal cognitive and imaging changes helped us define metabolic signatures 
correlated with disease progression. Key associations were also present in multiple 
independent cohorts. We believe that the systems approach taken in our study to elucidate 
metabolic changes along different stages during the progression of AD will transform our 
understanding of disease mechanisms and lead to valuable peripheral biomarkers that can 
inform and accelerate clinical trials.
2. Methods
2.1. Study cohorts and samples
2.1.1. ADNI-1 baseline samples—ADNI shipped 831 samples with unique identifiers 
belonging to 807 subjects. These initial identifiers were different from the ADNI subject 
identifiers. There were duplicate aliquots from the same CSF draw for 24 subjects to help us 
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evaluate analytical performance. Only after the final raw data were submitted to ADNI, the 
information was obtained to link the samples identifier to the subject RID and identify the 
duplicates.
Data were obtained from the ADNI database in September 2015 (http://adni.loni.usc.edu). 
ADNI-1 was launched in 2004 by the National Institute on Aging (NIA), the National 
Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, 
private pharmaceutical companies, and nonprofit organizations [31]. ADNI-1 patients 
underwent extensive clinical and cognitive testing, including the Alzheimer’s Disease 
Assessment Scale–Cognition (ADAS-Cog13), which was used as a measure of general 
cognition in this analysis. AD dementia diagnosis was established based on the NINDS-
ADRDA criteria for probable AD. Mild cognitive impairment (MCI) participants did not 
meet these AD criteria and had largely intact functional performance, meeting 
predetermined criteria for amnestic MCI [31]. Controls were cognitively normal (CN) 
(Supplementary Table 1). Additional details of participant selection criteria and protocol are 
available at http://www.adni-info.org and in the methods in the Supplementary Materials. 
The study was approved by institutional review boards of all participating institutions, and 
written informed consent was obtained from all participants and/or authorized 
representatives before study commencement.
2.1.2. Rotterdam and Erasmus Rucphen Family cohorts—Participants from the 
Erasmus Rucphen Family (ERF) study (N = 905) were metabolically profiled from fasting 
blood samples using the Biocrates AbsoluteIDQ-p150 kit platform (Supplementary Table 2) 
[32], which measures a subset of metabolites from the P180 and excludes many of the 
amines. A previously described quality control (QC) protocol was applied [32]. Valine was 
measured in fasting blood samples using the Brainshake platform [33] in 2752 participants 
from the Rotterdam large prospective cohort study [34]. Participants of the ERF study 
underwent a standardized cognitive test battery at the study center on the same day blood 
was drawn (Supplementary Table 2) [35]. Participants of the Rotterdam study underwent 
cognitive tests at the time of valine measurement, and all participants were followed up for 
AD clinical diagnosis [36], as previously described in detail [37].
The general cognitive ability or “g-factor” was calculated using previously described 
methods in dementia-free participants with available cognitive tests in the ERF study (N = 
905) and Rotterdam Study (N = 2480) [38]. In short, the g-factor is a general cognitive 
function phenotype created by principal component analysis of multiple cognitive tests. A 
higher g-factor is associated with a higher general cognitive function, in contrast to the 
cognitive measure used for analysis of the ADNI-1 cohort, the ADAS-Cog13.
2.1.3. The Indiana Memory and Aging Study—The Indiana Memory and Aging Study 
(IMAS) is an ongoing longitudinal study investigating multimodal neuroimaging, cognition, 
fluid biomarkers, and genetics in early prodromal stages of AD with follow-up visits every 
18 months [39–42]. IMAS participants included CN participants, euthymic older adults with 
subjective cognitive decline in the absence of significant psychometric deficits, and patients 
with amnestic MCI or probable AD (Supplementary Table 3). Because of limited sample 
size compared to other cohorts, analyses were limited to assessment of [11C] Pitts-burgh 
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compound B (PiB) positron emission tomography (PET) amyloid status. Thirty-four 
participants had PET scans to measure brain Aâ load; 30 participants underwent [11C]PiB 
PET scans on a Siemens HR + PET scanner; and 4 participants underwent [18F]Florbetapir 
PET scans on a Siemens mCT. For the [11C]PiB PET, participants underwent either a 90-
minute dynamic scan starting at time of tracer injection or a 50-minute dynamic scan after a 
40-minute uptake period after injection of approximately 10 mCi of [11C]PiB. The [18F] 
Florbetapir PET scans were collected as a 30-minute dynamic scan after a 40-minute uptake 
period after an injection of approximately 10 mCi of [18F]Florbetapir. [11C]PiB and 
[18F]Florbetapir scans were motion-corrected and normalized to Montreal Neurologic 
Institute space using parameters from a same time point structural magnetic resonance 
imaging (MRI) scan. For the [11C]PiB PET images, a 40- to 90-minute standardized uptake 
value ratio (SUVR) image was created by averaging the appropriate frames and intensity 
normalizing to mean cerebellar gray-matter uptake. For the [18F]Florbetapir PET, a 40- to 
70-minute SUVR image was created by averaging the appropriate frames and intensity 
normalizing to mean whole cerebellar uptake. Finally, amyloid positivity was defined as a 
mean [11C]PiB PET SUVR of ≥1.37 or a mean [18F]Florbetapir SUVR of ≥1.20 from a 
cortical gray-matter region of interest. These cutoffs were determined by simultaneous 
processing of the ADNI [11C] PiB and [18F]Florbetapir PET images using the same pipeline 
and adjusting the locally derived cutoffs to best match either the previously reported 
[11C]PiB PET cutoff of mean cortical SUVR ≥1.5 [43] or the [18F]Florbetapir PET cutoff of 
SUVR ≥1.10 [44], respectively. A side-by-side comparison of the three cohorts, including 
sample sizes, baseline cognitive diagnoses, and studied outcomes in each cohort, is offered 
in Supplementary Table 4.
2.2. AbsoluteIDQ-p180 kit metabolite measurements
Metabolites were measured with a targeted metabolomics approach using the AbsoluteIDQ-
p180 kit (BIOCRATES Life Science AG, Innsbruck, Austria), with an ultra-performance 
liquid chromatography (UPLC)/MS/MS system [Acquity UPLC (Waters), TQ-S triple 
quadrupole MS/MS (Waters)] which provides measurements of up to 186 endogenous 
metabolites quantitatively (amino acids and biogenic amines) and semiquantitatively 
(acylcarnitines, sphingomyelins, PCs, and lyso-glycero-phosphatidylcholines (a = acyl) 
[lysoPCs] across multiple classes) (see methods in Supplementary Materials). The 
AbsoluteIDQ-p180 kit has been fully validated according to European Medicine Agency 
Guidelines on bioanalytical method validation. In addition, plates include an automated 
technical validation to approve the validity of the run and provide verification of the actual 
performance of the applied quantitative procedure including instrumental analysis. The 
technical validation of each analyzed kit plate was performed using MetIDQ software based 
on results obtained and defined acceptance criteria for blank, zero samples, calibration 
standards and curves, low/medium/high-level QC samples, and measured signal intensity of 
internal standards over the plate. This is a highly useful platform that was used in hundreds 
of publications, including several studies in AD [11,12,15].
Deidentified samples were analyzed following the manufacturer’s protocol, with 
metabolomics laboratories blinded to diagnosis and pathological data. Serum samples from 
all 807 ADNI-1 participants were analyzed, but after QC, a smaller number of participants 
Toledo et al. Page 6













were included in the analysis (Supplementary Fig. 1). Three participants were excluded 
because of incomplete clinical data, 70 samples were excluded because of nonfasting status, 
and two samples were excluded during the multivariate outlier detection step (see the 
following), leaving 732 participants included in the final analyses. Each assay plate included 
two sets of replicates: (1) A set of duplicates obtained by pooling the first 72 samples in the 
study (QC pool duplicates) and (2) 20 blinded analytical duplicates (blinded duplicates).
2.3. P180 QC
Metabolites with >40% of measurements below the lower limit of detection (LOD) were 
excluded from the analysis. Metabolite values were scaled across the different plates using 
the QC pool duplicates. LOD values were imputed using each metabolite’s LOD/2 value. 
Using the blinded duplicates, we selected metabolites with a coefficient of variation <20% 
and an intraclass correlation coefficient >0.65. Based on the QC process, 32 of the flow 
injection analysis metabolites and 14 of the UPLC metabolites were excluded from further 
analysis (Supplementary Table 5). We checked for the presence of multivariate outlier 
participants by evaluating the first and second principal components in each platform. Two 
multivariate outliers were beyond 7 standard deviations and were therefore excluded. For the 
participants with duplicated measurements, we used the average values of the two measured 
values in further analyses.
2.4. CSF Aβ1–42 and tau biomarkers
Lumbar puncture was performed in the mornings after an overnight fast. Aβ1–42, total tau (t-
tau), and tau phosphorylated at threonine 181 (p-tau181) were measured using the multiplex 
xMAP Luminex platform (Luminex Corp, Austin, TX) with Innogenetics immunoassay kit-
based reagents (INNO-BIA AlzBio3; Ghent, Belgium; for research use– only reagents) 
(methods in Supplementary Materials) [45]. CSF samples were available and measured for 
48.8% of the CN, 52% of the MCI, and 54.9% of the AD participants. Aβ1–42-defined 
groups were classified as normal or pathological based on the previously published 
concentration (192 pg/mL) [46].
2.5. MRI measures
A 1.5-T MRI nonaccelerated sagittal volumetric 3D magnetization-prepared rapid gradient-
echo MRI images were acquired at each performance site for the ADNI-1 participants 
(http://www.adni-info.org; http://adni.loni.usc.edu). Only images that passed QC evaluations 
were included. Cortical gray-matter volumes were processed using the FreeSurfer version 
4.4 image processing framework (http://surfer.nmr.mgh.harvard.edu/) [47]. FreeSurfer 
ventricular volume of MRI scans that passed the QC was adjusted for total intracranial 
volume and used for longitudinal analyses. The Spatial Pattern of Abnormality for 
Recognition of Early Alzheimer’s Disease (SPARE-AD), an index that captures brain 
atrophy related to AD and has shown association with AD CSF biomarker and clinical 
measures, and was calculated for the baseline visit of ADNI-1 participants, was assessed in 
the present analysis [48,49].
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In the ADNI and IMAS cohort, 41 major medication classes used to treat psychiatric 
(including different categories of benzodiazepines, antipsychotics, and antidepressants) and 
cardiovascular conditions (including different categories of antihypertensives, cholesterol 
treatment, and antidiabetics), as well as dietary supplements (Co-Q10, fish oil, nicotinic 
acid, and acetyl L-carnitine), were systematically coded and available for model-based 
evaluations of the influence of each drug type on metabolite levels (methods in 
Supplementary Materials). Intake of any medication within a category was coded as present 
or absent. Dose effect was not evaluated. The list of the studied medication categories and 
the percentage of subjects taking these medications in each of the diagnostic categories for 
the ADNI cohort is listed in Supplementary Table 6.
2.7. Statistical analysis
Metabolites with a skewness >2 [50] that showed a departure of the normality distribution 
(D’Agostino test P-value <.05) [50,51] were log10 transformed to normalize their 
distribution. We implemented a two-stage regression approach, whereby metabolites were 
first adjusted for confounding medications and dietary supplements in a linear regression 
model. For each metabolite, medications were backward-selected via Bayesian information 
criteria to select an optimal combination of medications for preventing confounding while 
limiting model complexity. One AD medication class, that is, anticholinesterases, were 
excluded from this process due to highly significant correlations (Spearman’s ρ = 63.4%, P 
= 1.28 × 10−83) of these medications with diagnosis (for details, see methods in 
Supplementary Materials). The residuals for each metabolite were then carried forward to 
test associations with clinical outcomes.
The cross-sectional association with categorical outcomes (clinical diagnosis and CSF 
Aβ1–42 group) was studied using a logistic regression model. For the cross-sectional 
quantitative outcomes (t-tau/Aβ1–42 ratio, SPARE-AD, and ADAS-Cog13), a linear 
regression model was applied. Age and gender were forced covariates in all the models 
associating with clinical variables, and education was also forced into the models for ADAS-
Cog13 and clinical diagnosis, whereas APOE ε4 was backward-selected based on Bayesian 
information criteria for each outcome (see methods in Supplementary Materials and 
Supplementary Table 7). Diagnosis was not included as a covariate in the models in the 
primary analyses that studied Aβ1–42, t-tau/Aβ1–42 ratio, SPARE-AD, and ADAS-Cog13 
associations. The P-values were Bonferroni corrected to adjust for multiple comparisons and 
a corrected .05 two-tailed P-value was considered significant. A Cox hazard model including 
age, gender, APOE ε4 presence, and education as covariates was used to evaluate the 
association of metabolite levels with progression from MCI to AD with a median follow-up 
of 3.0 years (interquartile range [IQR]: 2.0–6.1). A mixed-effects model that included age, 
gender, education, APOE ε4 presence, time, and metabolite level as independent variables 
was used to study longitudinal associations between the metabolites and volumetric MRI 
changes (transformed to normalized distribution) during follow-up in the MCI participants 
(AD participants were excluded because of short follow-up) [52]. A mixed-effects model 
was also used to evaluate the association of metabolites with change in ADAS-Cog13 
(transformed to normalized distribution) and included education as an additional covariate. 
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Both models accounted for baseline cognitive and MRI measures for each participant. 
Median follow-up times for the MRI and cognitive analyses were 3.0 years (IQR: 2.0–5.0). 
An interaction with time was included in all mixed-effects models for the studied 
metabolites.
In the Rotterdam study, a linear regression model was fitted for the cross-sectional analysis 
with g-factor as the outcome and valine as the determinant, adjusting for age, gender, lipid-
lowering medication, and education. P-values and effect estimates of the significant 
metabolites are reported. [11C]PiB PET analysis for IMAS samples included age, gender, 
and APOE ε4 presence, along with the Aβ1–42 status on PET, as independent predictors of 
target metabolite measures using a linear regression model. All analyses were performed 
using the R software package [53].
2.7.1. Co-expression network construction and module analysis—We 
investigated the global baseline cross-sectional correlation structure of metabolites and their 
correlation with a subset of clinical and biomarker measures at baseline (Aβ1–42, tau/Aβ1–42 
ratio, and ADAS-Cog13). We built the p180 coexpression network based on baseline-
normalized data adjusted for age, education, gender, and APOE ε4 presence using the 
WGCNA R package [54].
2.7.2. Partial correlation analysis—Biochemically related metabolites and propagation 
patterns of effects on the clinical variables were investigated from a network perspective. A 
Gaussian graphical model (GGM) calculation was performed as described in Krumsiek et al. 
[55] using the GeneNet R package with default parameters. To illustrate effect propagation 
on clinical variables, we colored the resulting network similar to that in Mittelstrass et al. 
[56]. In brief, a GGM is an undirected graphical model based on partial correlation 
coefficients, that is, pairwise correlation coefficients conditioned against correlations with all 
other included variables. GGMs, contrary to correlation networks, thus can reveal the direct 
relations between metabolites. To account for correlations between metabolites and clinical 
or other potentially predictive variables, we used metabolite residuals that accounted for 
effects of medication and dietary supplements (as described previously) and additionally 
included age, gender, APOE ε4 presence, and education as covariates in the GGM 
generation process. To obtain significant partial correlations, we used a significance 
threshold of 0.05 after Bonferroni correction for all possible edges in the model (0.05/10,296 
= 4.86 × 10−6). For each clinical variable, we colored the network representation of the 
GGM using the results of our regression analyses using sign(β)*(−log10(P)) to visualize 
both strength of association and direction of effect.
3. Results
Metabolomic analyses were performed in the ADNI-1 cohort, and key findings were further 
tested in the Rotter-dam, EFR, and IMAS cohorts. Overall descriptions of sample size, 
composition, and studied outcomes across the different cohorts are shown in Supplementary 
Table 4. The results are presented for each cohort in the following.
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In ADNI-1, CN, MCI, and AD participants did not differ in mean age but, as expected, 
differed in APOE ε4 frequency, baseline cognition, MRI atrophy index, and CSF levels of T-
tau and Aβ1–42. The heat map (Fig. 1) (and the later described coexpression networks in 
Supplementary Fig. 2) shows that the global (i.e., direct and indirect) correlation structure 
between metabolites is formed into biochemical classes, illustrating that the metabolites with 
significant findings can be seen as proxies for the group of their correlating metabolites 
(Supplementary Material File 2 presents the correlation values).
3.2. ADNI-1: Metabolites associated with cross-sectional clinical, MRI, and CSF biomarker 
measures
The metabolites that remained in the analyses after the QC steps showed different 
correlation strengths, indicating groups of metabolites that may be involved in similar 
processes (Fig. 1). After applying Bonferroni multiple comparison correction, 13 
metabolites showed significant associations (Bonferroni-adjusted P-value <.05) with 
cognitive scores and CSF and MRI biomarker measures (Table 1). Six metabolites were 
associated with CSF Aβ1–42 positivity (ether-containing PC [PC ae] C36:2, PC ae C40:3, PC 
ae C42:4, PC ae C44:4, SM (OH) C14:1, SM C16:0), four were associated with t-tau/Aβ1–42 
ratio (C18, PC ae C36:2, SM C16:0, SM C20:2), five were associated with ADAS-Cog13 
scores (C14:1, C16:1, SM C20:2, α-aminoadipic acid [α-AAA], and valine), and 6 were 
associated with SPARE-AD scores (C12, C16:1, PC ae C42:4, PC ae C44:4, α-AAA, and 
valine). In all analyses, higher acylcarnitine, PC, and sphingomyelin (SM) values were 
associated with worse clinical and biomarker measures, whereas the opposite direction of 
associations was observed for valine and α–AAA values. The complete results for the 138 
studied metabolites are listed in Supplementary Table 8, where many amines (including 
isoleucine, glutamate, tyrosine, tryptophan, glycine, proline, histidine, T4OH proline) and 
other metabolites within PC and SM classes showed significant non–comparison-corrected 
associations with clinical markers and outcomes but did not survive Bonferroni multiple 
comparison correction. Supplementary Tables 9 and 10 present the analyses adjusted by 
clinical diagnosis and stratified by each of the three clinical diagnostic categories, 
respectively. All significant correlations were in the same directions in the clinical diagnostic 
groups.
We next evaluated differences in levels of key metabolites associated with cognitive or 
biomarker measures from the analyses reported previously between the three diagnostic 
groups (CN, MCI, and AD) subclassified by CSF Aβ1–42 positivity status. Metabolites 
showed three different patterns of associations with the CSF AD biomarkers. PC ae C44:4, 
PC ae C36:2, and C18 represented the most significant examples of each of these patterns, 
and the values in the six groups are shown in Fig. 2. Of note, CN participants (red boxes) 
with pathological CSF Aβ1–42 values showed significant metabolic changes in a specific 
group of metabolites compared with CN with no pathological CSF Aβ1–42 values (Fig. 2A). 
Some of the changes associated with CSF Aβ1–42 values appeared in clinical stages of 
disease (MCI and AD; Fig. 2B). Other metabolic changes were only observed in comparing 
CN participants to clinically impaired subjects (Fig. 2C) but showed no associations with 
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pathological CSF Aβ1–42 status. Fig. 2D illustrates valine correlation with cognition in the 
ADNI-1 study.
3.3. Metabolites associated with longitudinal outcomes in the ADNI-1 cohort
We evaluated whether levels of metabolites at baseline were associated with (1) ADAS-
Cog13 changes up to 5 years; (2) ventricular volume changes up to 5 years; or (3) 
progression from MCI to AD (Table 2). Regression coefficients of six metabolites (PC ae 
C40:3, PC ae C42:4, PC ae C44:4, SM (OH) C14:1, SM C16:0, and SM C20:2) showed a 
positive association with all three longitudinal outcomes. In addition, lower valine and α–
AAA values were associated with faster cognitive decline, similarly the coefficient for valine 
was negatively associated with ventricular volume changes. Fig. 3 shows some of these 
associations as examples, including Fig. 3A which shows the Cox hazards model of the 
association of SM C20:2 with conversion from MCI to AD, and Fig. 3B which shows the 
association between baseline concentration of SM 20:2 (presented as tertiles) and 
longitudinal cognitive (ADAS-Cog13) and MRI (brain ventricular volume) change.
3.4. Evaluation of findings in the Rotterdam and ERF studies
In the Rotterdam and ERF studies, only a subset of metabolites were measured from the 
panel of P180 metabolites evaluated in the ADNI-1 study (P150 panel, Supplementary Table 
11). Using a targeted approach, we tested whether the metabolites that showed a significant 
association in the ADNI-1 study were also correlated with cognition (general cognitive 
ability: g-factor) in the Rotterdam Study or ERF.
For the cross-sectional analysis, eight metabolites were available in the ERF study. Two of 
these metabolites (PC ae C40:3 and SM C20:2) were associated with cross-sectional general 
cognitive ability in the expected direction based on the discovery ADNI-1 cohort. Notice 
that higher general cognitive ability levels indicate better cognition as opposed to ADAS-
Cog13. Valine was strongly associated with a higher general cognitive ability (P =.00035) in 
the Rotterdam study (Fig. 2E), which is in line with the association with ADAS-Cog13 in 
ADNI-1 (Fig. 2D). Longitudinally, 342 participants developed AD in the Rotterdam study 
after a median follow-up time of 9.7 years (IQR 5.6–10.5). A Cox proportional hazard 
model was fitted adjusting for age at baseline, gender, education, and lipid-lowering 
medication and indicated that a 1-SD increase in valine concentration was also associated 
with a decreased risk of AD (P = .044).
3.5. Evaluation of Aβ1–42 signature in the IMAS cohort
Three of the six metabolites (PC ae 42:4, PC ae 44:4, and SM (OH) C14:1) that showed an 
association with CSF Aβ1–42 positivity in the ADNI-1 cohort were also associated with 
amyloid positivity on PET in the IMAS cohort (n = 34; Supplementary Table 12).
3.6. Partial correlation networks for Aβ1–42, T-tau, SPARE-AD, ADAS-Cog13—metabolic 
trajectory for disease
We strived to define insights into the trajectory of biochemical changes that correlate with 
established models for disease [30], Aβ pathology, tau, imaging changes, and cognitive 
decline, building partial correlation networks for each clinical measure.
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The partial correlation networks established direct connections between the measured 
metabolites, which have been shown to depict direct biochemical relationships between 
metabolites while omitting mediated correlations [55,57]. Fig. 4 integrates the strength of 
the partial correlations between metabolites and overlays on these networks the associations 
with the studied outcomes Aβ1–42 t-tau, SPARE-AD, and ADAS-Cog13 (partial correlation 
networks for p-tau and t-tau/Aβ1–42 ratio are not shown). The networks showing the direct 
links between metabolites (nodes) identified through their strong partial correlations (edges) 
expand the heat map information (Fig. 1). Through coloring of the metabolite nodes by their 
association to CSF, imaging, and cognitive markers, respectively (where bright colors 
indicate strong associations and blue and red color indicate upregulation and downregulation 
of metabolites), these networks demonstrate how the effects of clinical variables propagate 
along the edges within the network suggesting that the results follow biochemically 
plausible pathways. The studied outcomes cover the different stages of AD, matching known 
biomarkers of disease [30].
The network for Aβ1–42 (Fig. 4A) highlighted direct correlations with short- and medium-
chain SMs and PC with ether bonds, suggesting a role for membrane structure and function, 
contact sites, and membrane signaling in amyloid pathology. The correlation pattern for t-tau 
(Fig. 4B) highlighted metabolites among long-chain acylcarnitines and SMs implicated in 
lipid metabolism. The SPARE-AD and ADAS-Cog13 (Fig. 4B) partial correlation networks 
were very similar, suggesting associations of brain atrophy and cognitive decline with 
metabolic changes in BCAAs and short-chain acylcarnitines implicated in mitochondrial 
energetics as well as additional changes in lipid metabolism.
3.7. Coexpression network—direct and indirect connections for key metabolites
The partial correlation networks mentioned previously evaluated only direct connections 
among metabolites. To capture both indirect and direct correlations, we built coexpression 
networks to evaluate the number of modules in our data set and evaluate additional 
connections between key metabolites identified as related to cognitive or biomarker 
measures in ADNI-1. The full coexpression network, which identified seven metabolic 
modules, can be found in Supplementary Fig. 2, and Supplementary Material File 3 presents 
each of the individual correlations.
We investigated the correlation structure of the three metabolites in the ERF and Rotterdam 
data sets that significantly associated with cognition, namely PC ae C40:3, SM C20:2, valine 
as shown in Fig. 5. The subnet-work shows these three metabolites to have high correlations 
(marked as red edges) to other functional metabolic modules via direct and indirect links. 
Valine was highly correlated with isoleucine and α-AAA, whereas SM C20:2 was highly 
correlated with a subset of the SMs including SM C16:0. Finally, PC ae C40:3 was highly 
correlated with PCs and SMs, but not amines and acylcarnitines. These SMs and PCs were 
significantly associated with cognitive scores, CSF biomarkers, and MRI measures (Table 
1).
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The Alzheimer Disease Metabolomics Consortium (ADMC) funded by the NIA under the 
AMP-AD and MOVE-AD initiatives and in partnership with ADNI has as its goal to create a 
comprehensive metabolomics database for AD. These data will fill in biochemical 
knowledge about disease mechanisms that can be used as a roadmap for novel drug 
discovery and establishment of blood-based biomarkers. Eight complementary, targeted and 
nontargeted, metabolomics platforms are currently in the process of generating data on 
ADNI participants to define the metabolic trajectory of disease connecting central and 
peripheral metabolic failures in a pathway and network context. We seek to replicate earlier 
findings and test hypotheses but also expand on biochemical coverage to better understand 
disease pathogenesis by using complementary data unique to ADNI-1. The unique 
opportunity of having longitudinal cognitive and imaging data on each subject for close to a 
decade enables identification of peripheral biomarkers that are disease related.
This is the first report from ADMC on use of a targeted, highly validated metabolomics 
platform with the analysis guided by CSF markers and imaging data. Using 732 baseline 
serum samples from the ADNI-1 cohort, we systematically evaluated the relationships 
between metabolomics data and cross-sectional clinical, CSF, and MRI measures, as well as 
their association with longitudinal cognitive and brain volume changes. We demonstrate a 
novel approach to the analysis of neurodegenerative disease mechanisms. Multiple 
comparisons and covariate-adjusted analyses, that included relevant medications, identified 
sets of metabolites that became altered at specific disease stages (preclinical AD with 
biomarker-defined AD pathology vs. symptomatic stages) [30]. Using partial correlation 
networks, we integrate our findings of metabolic effects on AD pathogenesis, linking central 
and peripheral metabolism in a way that consistently reconciles biochemical trajectories of 
disease with this established temporal sequence of pathophysiological stages of AD. In the 
following, we therefore discuss our findings in their temporal order along AD pathogenesis.
4.1. Aβ pathology
Changes observed earliest in AD, namely in biomarker-defined preclinical stages [58] in CN 
participants, were higher levels of a specific set of PCs (PC ae C36.2, PC ae C40.3, PC ae 
C42.4, and PC ae C44.4) and SMs (SM (OH) C14.1, SM C16.0). These metabolites were 
associated with abnormal CSF Aβ1–42 values in CN participants to a similar degree as 
observed in MCI, indicating an early role of ether-containing PC species and SM in the 
development of the disease. Interestingly, most of these metabolites were also associated 
with later cognitive decline and global brain atrophy changes in the MCI group (Table 1). 
The use of information on AD CSF biomarkers was extremely useful and guided our 
metabolomics data. Only after substratification of the diagnostic groups (CN, MCI, and AD) 
based on CSF biomarkers, we were able to detect the increased values of these metabolites 
in participants with CSF pathology stressing the importance of using biomarkers to detect 
early biochemical changes [59]. Our findings along with those of several others [11,15] all 
point to problems with phospholipid metabolism that happen early in the disease process. 
These early changes by themselves are not sufficient predictors of disease or progression, 
but they might provide extremely valuable mechanistic insights.
Toledo et al. Page 13













Partial correlation networks showed that the pathological CSF Aβ1–42 values were 
associated with two groups of lipids, composed primarily of ether-containing PCs and 
relatively short-chain SMs. Ether-containing PC (PC ae) metabolites are PC species with an 
ether linkage of an aliphatic chain to the first hydroxyl position of glycerol. These lipids are 
not completely characterized and may represent a mixture of lipid metabolites including 
plasmalogens, acyl–alkyl PC, or PC containing an odd-numbered fatty acyl chain. When 
measured in the serum, the ether-containing lipids are derived from liver metabolism and are 
possible indicators of peroxisomal function and lipid oxidation status [60,61]. Plasmalogens 
and SMs are enriched in membrane rafts where they facilitate signal transduction and serve 
as a source for lipid secondary messengers [62]. The association of PCs and SMs in our 
study and others [14,63] with early changes in AD and with pathological CSF Aβ1–42 levels 
(Figs. 4B and 5) may be indicative of early neurodegeneration and loss of membrane 
function. Ether-linked PC metabolites are found in high abundance in plasma membranes 
and are a source for signaling molecules [64], particularly platelet-activating factor and 
arachidonic acid. Similarly, they are found in high abundance in immune cells, are 
regulatory factors, and may be part of the link between inflammation and AD [65]. Both 
SMs and ether-linked PCs may be located in membrane rafts, supporting the hypothesis that 
lipid rafts are directly associated with regulation of amyloid precursor protein processing, 
the production of Aβ1–42, and facilitate its aggregation [66]. All of these lipid biological 
functions related to Aβ1–42 might provide great insight about mechanisms of Aβ1–42 
pathology, but at this early stage, we cannot assign cause or effect. Because this study was 
conducted using peripheral blood, we cannot directly associate the changes in neuronal lipid 
rafts with changes in signaling and accumulation of cerebral Aβ1–42.
Previous smaller studies relying on clinical measures identified only associations between 
these metabolite categories and dementia diagnosis or clinical progression [12,15,67], 
indicating that these metabolic pathways may contribute significantly to AD 
pathophysiology. Differences in the specific metabolites identified in the published studies 
[12,15,67] may be due to differences in sample selection criteria, disease severity, or for the 
absence or presence of controlling for different confounders in the data analysis.
4.2. Tau pathology
In this study, pathological CSF Aβ1–42 shows an association with ether-linked PC, and 
shorter chain SM, but not amines, lysoPC, or acylcarnitines. Aβ1–42 changes happen early in 
disease, followed by accumulation of tau protein in the CSF [30]. In our analysis, tau-related 
metabolites were very different both from those that correlate with Aβ1–42 as well as from 
metabolites associated with brain atrophy and cognitive changes. Tau-related metabolites 
thus appear to belong to an intermediate stage between Aβ1–42 accumulation and changes in 
imaging and cognitive function (Fig. 4B), further supporting our hypothesis that different 
metabolic events occur at different disease stages.
Long-chain acylcarnitines, PC ae C36:2, and SM.C20:2 were higher only in cognitively 
impaired participants with AD-like CSF Aβ1–42 values, indicating that changes in these 
metabolites are more specific to AD-related neurodegeneration reflecting possible changes 
in multiple cellular processes. Specifically, accumulation of acylcarnitine species containing 
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long fatty acyl chains indicates malfunction of fatty acid transport and/or β-oxidation in 
mitochondria, inefficient utilization of fatty acids as energy substrates [68], or alterations in 
tau metabolism [69]. In the present study, we revealed that the levels of several acylcarnitine 
species were increased either at the MCI stage or in clinical AD [70] (Table 1). 
Acylcarnitines have important functions in the brain [70] such as mitochondrial function, 
energetics, and neurotransmission that need to be further explored and connected to 
peripheral function.
4.3. Brain volume changes and cognitive decline
In our study, partial correlation networks show a pattern of inverse associations between 
brain volume changes (measured by SPARE-AD) and cognition (ADAS-Cog13) and long 
and short acylcarnitines, valine, and α-AAA, indicating a shift in energy substrate utilization 
in later stages of AD (Fig. 4). By using a second type of networking analysis, a coexpression 
network, our data show the relationship between valine and short acylcarnitines (Fig. 5, dark 
green cluster), reinforcing the hypothesized changes in energetics. The association of the 
long-chain acylcarnitines, odd-numbered acylcarnitines, and amino acids in relation with 
ADAS-Cog scores supports a switch of utilization from fatty acids to amino acids and 
glucose. In the network analysis, the amines and short-chain acylcarnitines did not link to 
PCs and SMs, rather they clustered together in smaller groups. This may indicate that the 
short-chain acylcarnitines are associated in energy and amino acid metabolism rather than 
lipid metabolism in AD participants. This novel finding indicates a disease-associated 
transition in pathways for utilization of energy substrates. Whether such a switch is 
associated specifically with AD pathogenesis or is a function of aging [71] remains to be 
tested. Interestingly, ADAS-Cog13 does not show the associations with SMs or ether-linked 
PCs found with pathological CSF Aβ1–42. Therefore, it is possible that metabolic pathways 
other than those associated with lipid rafts are dys-regulated later in the disease process.
It is not clear if insulin resistance is a cause, an effect, or some combination of cause and 
effect in AD [72]. Insulin resistance, obesity, and diabetes are risk factors for AD [73], with 
lipid metabolism disorder (and inflammation) being a common link between metabolic 
disease, vascular disease, and AD. Several ether-linked PC metabolites have been associated 
with the risk of diabetes [74], insulin resistance promotes aminoacidemia and the use of 
amino acids for energy [68], and BCAA and α-AAA have been identified as predicting 
diabetes risk [75,76]. BCAAs (valine, leucine, and isoleucine) play central roles in 
metabolism and have been implicated in insulin resistance, type-2 diabetes mellitus, and 
obesity. Our findings in ADNI related to low levels of valine and its correlation with 
cognitive changes were confirmed in the large Rotterdam study, pointing to an important 
role for this BCAA in cognitive changes in AD. Low levels of BCAAs have been implicated 
in hepatic insulin resistance in liver disease and may have a broader role in insulin resistance 
in the brain [77]. The seemingly paradoxical directionality difference in correlation of 
BCAAs with diabetes and cognition needs to be further evaluated in longitudinal studies 
taking into account weight changes, tissue type, and differences in human and animal model 
systems [28,78]. Our understanding of the biochemical crossroads between diabetes and AD 
could be greatly enhanced by metabolic profiling of both central and peripheral tissues in 
both diseases and over time.
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In summary, by using metabolomics and network approaches, this study has revealed lipid 
metabolic changes related to early stages of disease, as well as later changes related to 
mitochondrial energetics and energy utilization. We hypothesize that the lipid changes 
measured in this study reflect alterations in membrane structure and function early in the 
disease process and suggest a change in lipid rafts, which in turn, cause alterations in Aβ 
processing [66]. We hypothesize that over time, the changes in lipid membranes, particularly 
mitochondrial membranes, results in increased lipid oxidation, loss of membrane potential, 
and changes in membrane transport [79,80]. All of these lipid membrane changes might be 
reflected as disruption in BCAA as an energy source, production of acylcarnitines, and 
altered energy substrate utilization. The link between the altered energy metabolism, 
glycolysis, use of ketone bodies, and development of insulin resistance are all subject of 
ongoing longitudinal studies using complementary metabolomics platforms that enable the 
study of those biochemical pathways. The specific interactions between the peripheral 
metabolic network changes, central changes, and the timeline of AD pathophysiology reveal 
that peripheral metabolic changes can impact long-term brain health and function. This 
study thus provides an approach to define viable disease biomarkers based on understanding 
of whole-body AD pathophysiology at a systems level.
Previous studies have shown seemingly conflicting results regarding the diagnostic and 
prognostic classification of metabolomics data in AD [11,15]. Our findings show that using 
a network approach, many of these findings might be related such as early changes in 
phospholipid metabolism. Large meta-analysis across many metabolomics studies using our 
network approaches is ongoing.
By using the unique data available as part of ADNI, we were able to establish robust 
associations accounting for several confounders that lead to a better understanding of 
metabolic changes present in AD. Gender showed the strongest associations with many 
metabolites, but also age, BMI, and several medications and food supplements, such as 
statins and fish oils, had significant effects on several metabolites. The fact that medication 
use varied among the groups (e.g., fish oil intake was more frequent in CN and MCI subjects 
while use of selective serotonin reuptake inhibitors was lower in CN subjects) and that 
sometimes studied groups are unbalanced in terms of demographics makes it imperative to 
account for all possible confounders. Our results thus suggest that future studies should 
account for associations of metabolites with both gender and medications. This is an 
important outcome, as prior studies have failed to address effects of medications on the 
metabolome; a limitation that can cause misleading conclusions. Many of the drugs used by 
AD patients were shown to have profound effects on metabolism (for reviews on drug 
effects see Kaddurah-Daouk and Weinshilboum [8,9]). A detailed analysis of medications as 
confounds and meta-analysis of previously reported metabolomics studies addressing 
confounds will be published separately.
Limitations of our study are several. At this early stage, we cannot determine which of the 
metabolic changes we see are causative and which are a consequence of disease. Future 
mechanistic studies in model systems are needed to test hypothesis generated along with 
building of predictive metabolic networks. Gender metabolic differences are clear from this 
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data set and although adjusted for in this study ongoing analysis and modeling of gender 
differences will be key. Profiling blood samples across the trajectory of disease will provide 
valuable information and is currently ongoing. In addition, analysis of CN cohort with 
normal CSF Aβ1–42 values will be useful to evaluate within subject variability. Linking 
peripheral and central metabolic changes in blood, CSF, and brain tissue is critical for better 
defining peripheral influences like diet and environment on brain health and disease. The 
effect of confounds like medications impacts metabolomics findings in significant ways and 
must be addressed carefully. In our study, we had medication data for two of the cohort 
(ADNI and IMAS), but this information was not available for the Rotterdam and ERF 
studies. Therefore, there are differences in how the data were processed across cohorts. 
Finally, neuropsychological assessments evaluated in the ADNI and Rotterdam and ERF 
scores were not the same. ADNI analyses were based on a global cognitive scale, whereas in 
the Rotterdam and ERF studies, a composite measure, the g-factor. Therefore, these scales 
might differently represent the summary of the diverse cognitive functions.
Over the past decade, we have gained significant knowledge about effects of commonly used 
medications and have tried to address their confounds in studies such as ADNI. More 
sophisticated modeling approaches will be needed to address complex interactions with 
medications so this study presents early effort. Defining genetic factors that influence 
metabolic changes is key and is ongoing. Broad biochemical coverage is needed to better 
define mechanism and trajectory of disease. The ADMC is producing metabolomics data 
sets from eight targeted and nontargeted platforms on the large ADNI cohort. After these 
and other cohort data sets are available, we look forward to working with the international 
scientific community to build a comprehensive model for AD using integrated multiomic 
network approaches.
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1. Systematic review: We searched PubMed and reviewed all publications 
reporting on the use of metabolomics technologies for defining signatures in 
plasma, serum, or cerebrospinal fluid (CSF) in Alzheimer’s disease (AD), 
mild cognitive impairment (MCI) when compared to healthy control subjects. 
Few small cohort studies have reported on findings with no replication and 
validation and results have been conflicting. Previous studies have not 
accounted for medication effects and did not include imaging or Aβ 
biomarkers for connecting peripheral and central changes.
2. Interpretation: Studying a large cohort of patients (AD, MCI, and cognitively 
normal) at different disease stages with guiding data on CSF and magnetic 
resonance imaging AD biomarkers, we identified peripheral metabolic 
changes in preclinical stages of disease and additional metabolic changes 
associated with imaging changes and cognitive decline. Results were 
validated in three additional cohorts (Rotterdam, Erasmus Rucphen Family, 
and Indiana Memory and Aging Study). Partial correlation networks and 
coexpression networks revealed progressive interconnected biochemical 
changes in disease.
3. Future directions: (1) Expand biochemical coverage and the number of 
metabolic processes studied, (2) continue to link peripheral and central 
metabolic changes, and (3) test which changes are causative and which are 
secondary to disease processes.
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Clustering of pairwise metabolite correlations and association results with clinical variables. 
(A) Heat map of Spearman correlations between the residuals of metabolite concentrations 
on the single metabolites. Metabolites are clustered using hierarchical clustering using the 
Euclidean distance metric. The clustering assigns metabolites to their biochemical class: 
amino acids, biogenic amines, short-chain and long-chain acylcarnitines, lyso-lipids, PC, 
and SM. Significant clusters of acylcarnitines are outlined in blue and amines outlined in 
brown. (B) Association results of the regression analyses. The distribution of association 
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results of metabolites with clinical variables mirrors the correlation structure of the 
metabolites. Abbreviations: α-AAA, α-aminoadipic acid; AD, Alzheimer’s disease; C0, free 
carnitine; Cx:y, acylcarnitines; Cx:y-OH, hydroxylacylcarnitines; Cx:y-DC, 
dicarboxylacylcarnitines; CN, cognitively normal; lysoPC, lyso-glycero-
phosphatidylcholines (a = acyl); MCI, mild cognitive impairment; Path. Aβ1–42, 
pathological Aβ1–42; PC, glycero-phosphatidylcholines (aa = diacyl, ae = acyl–alkyl); 
SDMA, symmetric dimethylarginine; SM, sphingomyelin; SMx:y, sphingomyelins; SM 
(OH) x:y, N-hydroxylacyloylsphingosyl-phosphocholine; T4-OH-Pro, trans-4-
hydroxyproline.
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Relationship between serum metabolites, clinical diagnosis, and Aβ1–42 status. Serum PC ae 
44:4 (A), PC ae 44:4 (B), and C18 (C) concentrations stratified by clinical diagnosis and 
CSFAβ1–42–defined groups. The concentration of each metabolite is shown for each 
diagnosis red: CN, green: MCI, blue: AD and by N. Abeta: normal concentrations of Aβ1–42 
(>192 pg/mL), and Path. Abeta: pathological concentrations of Aβ1–42 (<192 pg/mL), Y-
axes are values for each metabolite. Scatter plot for ADAS-Cog13 and serum valine values 
(D). Black line and shading are the regression line and 95% confidence interval. (D and E) 
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Correlations between valine levels and cognitive decline in ADNI-1 and Rotterdam, 
respectively. Abbreviations: α-AAA, α-Aminoadipic acid; ADAS-Cog13, Alzheimer’s 
Disease Assessment Scale–Cognition; ADNI-1, Alzheimer’s Disease Neuroimaging 
Initiative–1; C0, free carnitine; Cx:y, acylcarnitines; Cx:y-OH, hydroxylacylcarnitines; 
Cx:y-DC, dicarboxylacylcarnitines; lysoPC, lyso-glycero-phosphatidylcholines (a = acyl); 
PC, glycero-phosphatidylcholines (aa = diacyl, ae = acyl–alkyl); SDMA, symmetric 
dimethylarginine; SMx:y, sphingomyelins; SM (OH) x:y, N-hydroxylacyloylsphingosyl-
phosphocholine; T4-OH-Pro, trans-4-hydroxyproline.
Toledo et al. Page 28














Longitudinal associations for SM C20:2. (A) Cox hazards model of the association of 
conversion from MCI to AD. Black line: 1st tertile, red line: 2nd tertile, green line: 3rd 
tertile. Analysis was conducted using quantitative values, and stratification by tertiles was 
used only for graphical representation. (B) Association between baseline concentrations of 
SM 20:2 and longitudinal cognitive (ADAS-Cog13) and imaging (MRI: brain ventricular 
volume) changes during follow-up. Lines represent trajectories on subjects on the 25th 
percentile (black line), 50th percentile (red line), 75th percentile (green line) of baseline SM 
20:2. Y-axes are ADAS-Cog13 score (left) and ventricular volume (right). Trajectories for 
these values are calculated based on the studied mixed-effects models. Abbreviations: AD, 
Alzheimer’s disease; ADAS-Cog13, Alzheimer’s Disease Assessment Scale–Cognition; 
MCI, mild cognitive impairment; MRI, magnetic resonance imaging.
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Network model showing metabolic pathways correlated with the temporal evolution of 
biomarkers and clinical variables in AD. (A) Partial correlation network. Gaussian graphical 
model of metabolite concentrations showing reconstructed metabolic pathways and 
highlighting of the different modules involved in the steps along the temporal evolution of 
biomarkers and clinical variables in AD. Nodes in the network represent the metabolites, and 
edges (lines) illustrate the strength and direction of their partial correlations. Only partial 
correlations significant after Bonferroni correction for all possible edges are included. 
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Labels show the major classes of metabolites included in our study. Gray circles outline the 
modules highlighted in panel B. (B) Schematic diagram of the model of temporal evolution 
of biomarkers in AD, modified from Jack and Holtzman [30], augmented with colored 
versions of the network from panel A. In these networks, nodes are highlighted according to 
the strength and direction of the metabolite’s association with the respective clinical trait 
with blue as positive and red as negative (networks in temporal order from left to right: 
pathological Aβ1–42, T-tau, SPARE-AD, and ADAS-Cog13). Significant associations are 
colored in dark blue/bright red, and weaker (but at least nominally significant at 0.05) 
associations are displayed in fainter colors. Modules of metabolites implicated in the 
respective trait are highlighted by circles colored by their first occurrence in the temporal 
order following the color scheme of the time sequence on the bottom. The partial correlation 
network for Aβ1–42 (panel A) highlighted direct correlations with short- and medium-chain 
SM and PC with ether bonds suggesting a role for membrane structure and function, contact 
sites, and membrane signaling in amyloid pathology. There was a different pattern for tau 
(panel B) with highlighted metabolites with long-chain acylcarnitines and SM implicated in 
lipid metabolism showing association with T-tau level. The SPARE-AD and ADAS-Cog13 
partial correlation networks were very similar suggesting associations of brain atrophy and 
cognitive decline with metabolic changes in BCAAs and short-chain acylcarnitines that have 
been implicated in mitochondrial energetics as well as additional changes in lipid 
metabolism. Abbreviations: AD, Alzheimer’s disease; ADAS-Cog13, Alzheimer’s Disease 
Assessment Scale–Cognition; BCAA, branched-chain amino acid; PC, glycero-
phosphatidylcholines (aa = diacyl, ae = acyl–alkyl); SM, sphingomyelin; SPARE-AD, 
Spatial Pattern of Abnormalities for Recognition of Early AD.
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Coexpression subnetwork with direct and indirect interconnections between select 
metabolites. A coexpression subnetwork focused on three metabolites also identified in the 
Rotterdam data set (PC ae C40:3, valine, and SM C20:2) was generated from the primary 
network (Supplementary Fig. 2). The subnetwork shows these three metabolites have high 
correlations (red edges lines) and lower correlations (green edges lines) to multiple modules 
via direct and indirect interconnections. Each module is denoted by a color representing a 
robust set of coregulated metabolites in interconnected biochemical pathways, for example, 
orange module contained a subset of amines, green module consists of long-chain 
acylcarnitines; teal, brown, and blue modules contained exclusively PC and lysoPC; red 
module contained SM and PC; gray module contained short-chain acylcarnitines and other 
amines. Each node represents a metabolite. The edge (line) opacity is proportional to the 
Pearson correlation, that is, lighter means weaker correlation value and darker means 
stronger correlation. The intermodule edges represent correlations and potentially indirect 
interactions among metabolites and biochemical pathways. The coexpression network 
captures all significant associations between metabolites and reveals a global correlation 
structure and interconnections among different modules that adds to our understanding of 
the disease network. Abbreviations: lysoPC, lyso-glycero-phosphatidylcholines (a = acyl); 
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PC, glycero-phosphatidylcholines (aa = diacyl, ae = acyl–alkyl); PC ae, ether-containing PC; 
SM, sphingomyelin.
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Table 2
Association of metabolites with longitudinal cognitive and MRI changes in MCI
Analytes ADAS-Cog13 change Ventricle volume change Progression MCI to AD dementia
C12 0.091 (.26) 0.11 (.73) 1.37 (.4)
C14:1     1.39 (.034) 7.085 (.006)   2.11 (.22)
C16:1   0.15 (.13)   0.67 (.092)     1.9 (.19)
C18 −0.16 (.87) 1.94 (.64)   2.41 (.18)
PC ae C36:2 0.0075 (.094) 0.031 (.096)   1.056 (.012)
PC ae C40:3   0.38 (.02)     1.5 (.020)     5.98 (.027)
PC ae C42:4   0.15 (.04)   0.72 (.013)     1.96 (.042)
PC ae C44:4       0.49 (.0076)     2.33 (.0012)     5.89 (.027)
SM (OH) C14:1 0.015 (.04) 0.075 (.01)      1.08 (.025)
SM C16:0 0.0009 (.025) 0.0037 (.023)    1.004 (.029)
SM C20:2       0.11 (.0078)     0.48 (.0035)         1.9 (.0023)
α-AAA −0.093 (.022) −0.29 (.087)     0.68 (.061)
Valine −0.0006 (.035)  −0.0027 (.026)        1.0 (.27)
Abbreviations: MRI, magnetic resonance imaging; MCI, mild cognitive impairment; ADAS-Cog13, Alzheimer’s Disease Assessment Scale–
Cognition; AD, Alzheimer’s disease; PC ae, ether-containing PC; α-AAA, α-aminoadipic acid.
NOTE. Table depicts the association between selected metabolites and longitudinal ADAS-Cog13 (column 2) and ventricular volume (column 3) in 
mixed-effects models that were age, gender, and APOE adjusted. In addition, the ADAS-Cog13 model was adjusted for education. Boxes contain 
the coefficients and, in parenthesis, the P-values. The last column (column 4) presents the associations of the metabolites with progression from 
MCI to AD in Cox hazards models that included age, gender, education, and APOE as covariates. Values represent hazard ratio and, in parenthesis, 
the P-values. Significant associations are bolded for an easier visualization. All P-values were not multiple comparison corrected.
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